Health / WORLD

UK MHRA grants conditional approval for triheptanoin in rare metabolic disorders

The UK Medicines and Healthcare products Regulatory Agency approved triheptanoin (Dojolvi) on 30 October as an oral liquid for adult and paediatric patients with long-chain fatty acid oxidation disorders. The regulatory decision was granted as a conditional marketing authorisation.

Reading sizeSources ↓Share story ↗
Conceptual illustration of public health, research and connected data.Illustration
Symbolic illustration

Long-chain fatty acid oxidation disorders are rare genetic conditions that disrupt how the body converts long-chain fats into cellular energy, creating severe risks of cardiomyopathy, muscle breakdown and acute hypoglycemia. Triheptanoin, a synthetic odd-carbon medium-chain triglyceride, functions as a direct nutritional energy source to bypass defective enzymatic pathways in the Krebs cycle.

The MHRA noted that conditional authorisation requires ongoing submission of pediatric clinical efficacy and safety data to support full marketing approval. Common reported side effects include gastrointestinal symptoms such as abdominal pain, diarrhoea and nausea. The decision authorizes clinical prescribing under supervised dietary management rather than universal availability across all pharmacy channels.

Data

Timeline

Source publication

Publication of the official conditional marketing authorisation announcement on 30 October 2026.

  1. · Occurred

    MHRA issues conditional marketing authorisation for triheptanoin

    Official approval announced on 30 October 2026 for treating long-chain fatty acid oxidation disorders.

Methodology

The date records publication of the cited primary source. Clinical indications and regulatory constraints are stated in the article.

Updated:

Structured coverage

Subjects and places

Subject proposals

Geographic references

Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.

  • United Kingdom · Place role: Coverage · Place type: Country or area · Location precision: Regional
    Evidence
    • Explicit preserved editorial country/region; no city or national centroid inferredwww.gov.uk ↗
Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Health

UK MHRA extends Casgevy gene-editing approval to children aged five and over

The UK Medicines and Healthcare products Regulatory Agency announced on 29 October that it has expanded the authorisation for the CRISPR-based gene therapy Casgevy to children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassaemia.

Medicines and Healthcare products Regulatory Agency, United Kingdom1 min read Data included
Health

UK confirms indefinite recognition of CE-marked medical devices in Great Britain

The UK government and MHRA announced on 21 October that medical devices certified under the EU Medical Devices Regulation and In Vitro Diagnostic Regulation will be recognized indefinitely in Great Britain, while legacy directive transition timelines are extended to 2028.

Medicines and Healthcare products Regulatory Agency, United Kingdom1 min read Data included